U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Poorly differentiated thymic neuroendocrine carcinoma

MedGen UID:
931135
•Concept ID:
C4305466
•
Neoplastic Process
Synonyms: poorly differentiated thymic neuroendocrine carcinoma; Poorly-differentiated neuroendocrine carcinoma of thymus; Poorly-differentiated thymic neuroendocrine carcinoma
SNOMED CT: Poorly-differentiated neuroendocrine carcinoma of thymus (717921000); Poorly-differentiated thymic neuroendocrine carcinoma (717921000)
Modes of inheritance:
Not genetically inherited
MedGen UID:
988794
•Concept ID:
CN307044
•
Finding
Source: Orphanet
clinical entity without genetic inheritance.
See: This record
Not genetically inherited (Orphanet)
 
Monarch Initiative: MONDO:0016978
Orphanet: ORPHA263339

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPoorly differentiated thymic neuroendocrine carcinoma

Professional guidelines

PubMed

Clinicopathological features and current treatment outcomes of neuroendocrine thymic tumours.
Fang W, Filosso PL, Roden AC, Gu Z, Liu Y, Agzarian J, Shen RK, Ruffini E
Eur J Cardiothorac Surg 2021 May 8;59(5):1004-1013. doi: 10.1093/ejcts/ezaa453. PMID: 33367634

Curated

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023

Recent clinical studies

Etiology

Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O
Endocr Pathol 2022 Mar;33(1):27-63. Epub 2022 Mar 14 doi: 10.1007/s12022-022-09707-3. PMID: 35288841
Clinicopathological features and current treatment outcomes of neuroendocrine thymic tumours.
Fang W, Filosso PL, Roden AC, Gu Z, Liu Y, Agzarian J, Shen RK, Ruffini E
Eur J Cardiothorac Surg 2021 May 8;59(5):1004-1013. doi: 10.1093/ejcts/ezaa453. PMID: 33367634
Survival outcomes of patients with high-grade and poorly differentiated thymic neuroendocrine carcinoma.
Hamaji M, Omasa M, Nakagawa T, Miyahara S, Suga M, Kawakami K, Aoyama A, Date H
Interact Cardiovasc Thorac Surg 2020 Jul 1;31(1):98-101. doi: 10.1093/icvts/ivaa059. PMID: 32386314
Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.
Uccella S, La Rosa S, Volante M, Papotti M
Endocr Pathol 2018 Jun;29(2):150-168. doi: 10.1007/s12022-018-9522-y. PMID: 29520563
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S, Garagnani L, Sartori G, Calabrese F, Marchetti A, Buttitta F, Felicioni L, Migaldi M, Rea F, Di Chiara F, Mengoli MC, Rossi G
Ann Oncol 2012 Sep;23(9):2409-2414. Epub 2012 Feb 21 doi: 10.1093/annonc/mdr626. PMID: 22357254

Diagnosis

Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O
Endocr Pathol 2022 Mar;33(1):27-63. Epub 2022 Mar 14 doi: 10.1007/s12022-022-09707-3. PMID: 35288841
Clinicopathological features and current treatment outcomes of neuroendocrine thymic tumours.
Fang W, Filosso PL, Roden AC, Gu Z, Liu Y, Agzarian J, Shen RK, Ruffini E
Eur J Cardiothorac Surg 2021 May 8;59(5):1004-1013. doi: 10.1093/ejcts/ezaa453. PMID: 33367634
Survival outcomes of patients with high-grade and poorly differentiated thymic neuroendocrine carcinoma.
Hamaji M, Omasa M, Nakagawa T, Miyahara S, Suga M, Kawakami K, Aoyama A, Date H
Interact Cardiovasc Thorac Surg 2020 Jul 1;31(1):98-101. doi: 10.1093/icvts/ivaa059. PMID: 32386314
Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.
Uccella S, La Rosa S, Volante M, Papotti M
Endocr Pathol 2018 Jun;29(2):150-168. doi: 10.1007/s12022-018-9522-y. PMID: 29520563
Primary thymic carcinomas.
Wick MR, Scheithauer BW, Weiland LH, Bernatz PE
Am J Surg Pathol 1982 Oct;6(7):613-30. doi: 10.1097/00000478-198210000-00003. PMID: 6295194

Therapy

Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.
Hirai F, Seto T, Inamasu E, Toyokawa G, Yoshida T, Nosaki K, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y
Anticancer Res 2014 Oct;34(10):5743-7. PMID: 25275083
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S, Garagnani L, Sartori G, Calabrese F, Marchetti A, Buttitta F, Felicioni L, Migaldi M, Rea F, Di Chiara F, Mengoli MC, Rossi G
Ann Oncol 2012 Sep;23(9):2409-2414. Epub 2012 Feb 21 doi: 10.1093/annonc/mdr626. PMID: 22357254

Prognosis

Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O
Endocr Pathol 2022 Mar;33(1):27-63. Epub 2022 Mar 14 doi: 10.1007/s12022-022-09707-3. PMID: 35288841
Survival outcomes of patients with high-grade and poorly differentiated thymic neuroendocrine carcinoma.
Hamaji M, Omasa M, Nakagawa T, Miyahara S, Suga M, Kawakami K, Aoyama A, Date H
Interact Cardiovasc Thorac Surg 2020 Jul 1;31(1):98-101. doi: 10.1093/icvts/ivaa059. PMID: 32386314
Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.
Uccella S, La Rosa S, Volante M, Papotti M
Endocr Pathol 2018 Jun;29(2):150-168. doi: 10.1007/s12022-018-9522-y. PMID: 29520563
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S, Garagnani L, Sartori G, Calabrese F, Marchetti A, Buttitta F, Felicioni L, Migaldi M, Rea F, Di Chiara F, Mengoli MC, Rossi G
Ann Oncol 2012 Sep;23(9):2409-2414. Epub 2012 Feb 21 doi: 10.1093/annonc/mdr626. PMID: 22357254
Thymic neuroendocrine carcinomas with combined features ranging from well-differentiated (carcinoid) to small cell carcinoma. A clinicopathologic and immunohistochemical study of 11 cases.
Moran CA, Suster S
Am J Clin Pathol 2000 Mar;113(3):345-50. doi: 10.1309/Q01U-60BL-VEV4-TWR1. PMID: 10705813

Clinical prediction guides

Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A, Witkowska M, Wójcik-Giertuga M, Kuśnierz K, Bocian A, Walter A, Rydel M, Robek A, Pierzchała S, Malczewska M, Leś-Zielińska I, Czyżewski D, Ziora D, Pilch-Kowalczyk J, Zajęcki W, Kos-Kudła B
Neuroendocrinology 2021;111(4):304-319. Epub 2020 Apr 24 doi: 10.1159/000508106. PMID: 32335553
Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.
Hirai F, Seto T, Inamasu E, Toyokawa G, Yoshida T, Nosaki K, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y
Anticancer Res 2014 Oct;34(10):5743-7. PMID: 25275083
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S, Garagnani L, Sartori G, Calabrese F, Marchetti A, Buttitta F, Felicioni L, Migaldi M, Rea F, Di Chiara F, Mengoli MC, Rossi G
Ann Oncol 2012 Sep;23(9):2409-2414. Epub 2012 Feb 21 doi: 10.1093/annonc/mdr626. PMID: 22357254
Thymic carcinoma. A clinicopathologic study of 60 cases.
Suster S, Rosai J
Cancer 1991 Feb 15;67(4):1025-32. doi: 10.1002/1097-0142(19910215)67:4<1025::aid-cncr2820670427>3.0.co;2-f. PMID: 1991250

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • NCCN, 2023
      NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023

    Reviews

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...